Two new studies published on Wednesday of patients with breast and prostate cancers add to growing evidence that detecting bits of cancer DNA circulating in the blood can guide patient treatment.
Enthusiasm is building for "liquid biopsies," which offer a noninvasive alternative to standard tissue biopsies and are expected to be a multibillion-dollar market.
But a key question remains: Do they really work?